Pfizer's Kindler can't quash mega-deal talk

Kids who want ice cream won't take no for answer. Neither, apparently, will some Pfizer investors, who are clamoring again for a big acquisition just days after CEO Jeff Kindler said he wouldn't play Let's Make a Deal. Mega-M&A is just too disruptive, Kindler said at last Wednesday's analyst confab. And he should know: He's leading a company that's still absorbing Warner-Lambert and Pharmacia.

Nonetheless. A CreditSuisse analyst maintains that "a large scale deal may be the best option" for shoring up the company as it nears the loss of its biggest money-maker, Lipitor, to generic competition. And the analyst has a couple of ideas about which companies to pursue, namely Wyeth and Amgen.

So, the Wall Street Journal's Health Blog has posted a basketball tournament-style bracket of pharma deals, pairing Pfizer with Amgen and Merck with Schering-Plough, plus a few other big names we'll leave it to you to find out. We won't be placing any bets on these deals, but who knows. Considering the state of the market these days, anything might happen.

- see the item at the WSJ Health Blog

Related Articles:
Is Pfizer eyeing Chinese outsourcing? Report
Pfizer plots big outsourcing push. Report
Analysts not impressed with Pfizer. Report
Pfizer seeks salvation in late-stage biotherapeutics. Report
Is Pfizer's CEO as bold as promised? Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.